A Phase I Open Label, Placebo-controlled Dose Escalation Study to Evaluate Safety and Pharmacokinetics of NatrunixTM Via Subcutaneous Injection in Healthy Subjects
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Vilamakitug (Primary)
- Indications Colorectal cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors XBiotech
- 07 Feb 2022 Status changed from not yet recruiting to recruiting.
- 10 Nov 2021 New trial record